ContactContact
Further growth through continuation of buy-and-build strategy
€17.8mn
Equity investment
€8mn
Revenues 2020
87
Employees 2020

KEY FACTS AT A GLANCE

  • Treatment of patients in nephrology (kidney medicine) including dialysis
  • Aim is to build a sustainable structure for the promotion and delivery of home dialysis
  • Growth through continuation of the buy-and-build strategy

operasan

Investment by
DBAG FUND VII

€17.8MN

DBAG'S INTEREST

€3.2MN

MANAGEMENT BUYOUT

MAJORITY
INVESTMENT OF
DBAG FUND VII

First invested

JANUARY 2021

REVENUES in €mn

 

3

 

2018

 

7

 

2019

 

8

 

2020

As of 30 June 2021

4.000

patients are regularily treated by operasan in its centers

With the investment in operasan, our commitment to the healthcare focus sector is growing. With an experienced team, all the foundations have been laid to create a leading provider in nephrology care.

LUCAS HERBERT
MANAGING DIRECTOR

PROFILE

operasan treats patients in nephrology (kidney medicine) including dialysis. This is done in cooperation with physicians in private practice and in the company's own medical care centers. The aim is to provide high-quality patient care as close as possible to the patient, ideally in the patient's home environment or in the nursing home providing care.

The aim of operasan is to establish a sustainable structure for the promotion and implementation of home dialysis. operasan assumes responsibility for dialysis vis-à-vis patients, health insurance companies and the associations of panel doctors. It relieves the cooperating physicians of all organizational and administrative tasks, allowing them to focus on their medical work. All home dialysis procedures are taken into account, hemodialysis as well as peritoneal dialysis. The care of patients in their home environment is just as much in the foreground of the work as the care in specially qualified facilities for inpatient care and care for the elderly.

What is needed is a tightly knit and efficiently organized network of medical facilities, hospitals, outpatient and inpatient care facilities, health insurance companies and associations of panel doctors, pharmacies and pharmaceutical companies, as well as the supplying industry. 

POTENTIAL FOR DEVELOPMENT

The task and objective of operasan is to set up, organize and operate the network, which is called dialysis@home. The aim is to increase the share of home dialysis in Germany to over 20 per cent within ten years.

 

 

 

 

Responsible team member

Lucas Herbert
Lucas Herbert

Managing Director

Lucas Herbert
+49 69 95787-208

Lucas Herbert

Managing Director

Lucas Herbert joined Deutsche Beteiligungs AG in 2007 and became a Managing Director in 2015.

Lucas Herbert has 13 years of experience in the private equity sector. During this time, he has gained extensive knowledge, particularly in the IT services/software, mechanical and plant engineering and healthcare sectors. Lucas Herbert has been involved in a large number of corporate investments and disposals. These include Romaco, Spheros, Gienanth and Silbitz. He also led the investment process in blikk, Cloudflight and operasan.

He holds a Master of Science in Business Administration from the Rotterdam School of Management, Erasmus University, and also studied at the Maastricht University and the University of Newscastle, Australia.

Current portfolio companies

Silbitz Gienanth

Former portfolio companies

Lucas Herbert

Managing Director

+49 69 95787-208